Human ES cell-derived MSC spheroids encapsulated in polydopamine nanoparticle-modified GelMA hydrogel enhance diabetic wound healing

Read full text
Authors: Jinjie Wu, Guihui Qin, Xiaoyan Wang, Ye Yi, Ren-He Xu
Cited by: 1
References: 60

Abstract

Mesenchymal stromal cell (MSC)-based strategies hold promises for treating diabetic foot ulcers. However, the hostile microenvironment of the lesions characterized by hypoxia, oxidative stress, and chronic inflammation impairs the survival and efficacy of transplanted MSCs. Here, we developed a composite bio-dressing by integrating MSC spheroid (Sp) derived from human embryonic stem cells via trophoblast intermediates (T-MSC) with gelatin methacryloyl hydrogel (Gm) and polydopamine nanoparticles (Pn). The GmPn matrix exhibited excellent adaptability, adhesion, porosity, biodegradability, and biocompatibility. Compared to monolayer-cultured T-MSCs, T-MSC Sp with scalable production via hanging drop demonstrated greater resilience to hypoxia and enhanced the migration and tube formation of vascular endothelial cells by secreting higher levels of chemokines and growth factors, verified by RNA-Seq and cytokine array. Furthermore, the combination of T-MSC Sp with Pn provided superior antioxidant, cell protection, and inflammation-regulatory effects compared to either component alone. The integration of T-MSC Sp, Gm, and Pn resulted in a bio-dressing termed SpGmPn, which accelerated wound area closer compared to Sp alone, owing to the synergistic effects of its components in stage-dependent immunomodulation and enhanced tissue regeneration. Thus, SpGmPn represents a promising and scalable therapeutic strategy for enhancing diabetic wound repair beyond the capabilities of T-MSC Sp alone.

Fields of Study & Subjects

Wound Healing and Treatments Mesenchymal stem cell research Tissue Engineering and Regenerative Medicine

Publication details

Journal / source
Journal of Nanobiotechnology
Publisher
Springer Science and Business Media LLC
Volume
24
Issue
1
Pages
129–129
Publication date
3 February 2026
Language
EN